Thursday, January 12, 2017

Biomarkers in Cardiovascular Diseases



Biomarkers in Cardiovascular Diseases


The establishment of precise and reliable biomarker tests for the early stages of cardiovascular disease is of great importance and can be the cornerstone in the prevention of future cardiovascular disease (CVD). Furthermore, some biomarkers may provide important information concerning the pathogenesis of CVD or appear to be useful in risk stratification, in CVD diagnosis, or in monitoring therapy; many others may be risk factors themselves, representing therefore potential targets of therapy. The ideal biomarker should have the following characteristics: highly sensitive, specific, reliable. Read more...
Table of contents : 

Content: Front Cover; Preface; Contents; Part I: Classical Biomarkers; Chapter 1: C-Reactive Protein in Cardiovascular Disease; Chapter 2: Biomarkers in Early Atherosclerosis; Chapter 3: Biomarkers in Essential Hypertension; Chapter 4: Biomarkers in Hyperlipidemia; Chapter 5: Cardiac Biomarkers in Acute Coronary Syndromes; Chapter 6: Biomarkers in Congestive Heart Failure; Chapter 7: Biomarkers of Pulmonary Hypertension and Pulmonary Embolism; Chapter 8: Coronary Artery Bypass Grafting and Biomarkers; Chapter 9: Biomarkers of Peripheral Arterial Disease; Chapter 10: Biomarkers in Cardiorenal Syndrome. Chapter 11: Cardiac Arrhythmias: Is there a Role for Biomarkers?Chapter 12: The Role of Biomarkers in Antiplatelet Treatment; Part II: Novel Biomarkers; Chapter 13: Novel Biomarkers Used in the Assessment of Acute Coronary Syndrome; Chapter 14: Novel Cardiac Biomarkers and Application to Heart Failure; Chapter 15: The Role of Genetic Traits in Cardiovascular Disease; Chapter 16: MicroRNAs: A Novel Cardiac Biomarker.
Abstract: The establishment of precise and reliable biomarker tests for the early stages of cardiovascular disease is of great importance and can be the cornerstone in the prevention of future cardiovascular disease (CVD). Furthermore, some biomarkers may provide important information concerning the pathogenesis of CVD or appear to be useful in risk stratification, in CVD diagnosis, or in monitoring therapy; many others may be risk factors themselves, representing therefore potential targets of therapy. The ideal biomarker should have the following characteristics: highly sensitive, specific, reliable